Explorative Evaluation of the Impact of Severe Premenstrual Disorders on Work Absenteeism and Productivity

Women's Health Issues

Volumn 20, Issue 1, 2010, Pages 58-65

  Heinemann, Lothar A J ^a   Minh, Thai Do ^a   Filonenko, Anna ^b   Uhl Hochgräber, Kerstin ^b  

^a Berlin Center for Epidemiology and Health Research   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; QUALITY OF LIFE; QUESTIONNAIRE; SCREENING TEST; WOMEN'S HEALTH; WORK DISABILITY;

ABSENTEEISM; ADOLESCENT; ADULT; ALGORITHMS; COST OF ILLNESS; EFFICIENCY; EMPLOYMENT; FEMALE; GERMANY; HUMANS; MIDDLE AGED; PREMENSTRUAL SYNDROME; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; WOMEN'S HEALTH; YOUNG ADULT;

EID: 72749121366     PISSN: 10493867     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.whi.2009.09.005     Document Type: Article

References (21)

1. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin 15. Premenstrual syndrome: Clinical management guidelines for obstetricians-gynecologists (2000), ACOG, Washington, DC
2. American Psychiatric Association. Premenstrual dysphoric disorder. Diagnostic and statistical manual of mental disorders (4th ed., Text Revision; pp. 771-774) (2000), Author, Washington, DC
3. Borenstein J.E., Dean B.B., Endicott J., Wong J., Brown C., Dickerson V., et al. Health and economic impact of the premenstrual syndrome. Journal of Reproductive Medicine 48 (2003) 515-524
4. Borenstein J.E., Dean B.B., Leifke E., Korner P., and Yonkers K.A. Differences in symptom scores and health outcomes in premenstrual syndrome. Journal of Womens Health (Larchmont) 16 (2007) 1139-1144
5. Busch C.M., Costa Jr. P.T., Whitehead W.E., and Heller B.R. Severe perimenstrual symptoms: prevalence and effects on absenteeism and health care seeking in a non-clinical sample. Women & Health 14 (1988) 59-74
6. Chawla A., Swindle R., Long S., Kennedy S., and Sternfeld B. Premenstrual dysphoric disorder: is there an economic burden of illness?. Medical Care 40 (2002) 1101-1112
7. Drummond M.L., Sculpher M.J., Torrance G.W., O'Brien B.J., and Stoddardt G.L. Methods for the economic evaluation of healthcare programmes. 3rd ed. (2005), Oxford University Press, Oxford
8. Endicott J., Nee J., and Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Archives of Women's Mental Health 9 (2006) 41-49
9. Freeman E.W., and Sondheimer S.J. Premenstrual Dysphoric Disorder: Recognition and Treatment. Primary Care Companion to the Journal of Clinical Psychiatry 5 (2003) 30-39
10. Halbreich U., Borenstein J., Pearlstein T., and Kahn L.S. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28 Suppl 3 (2003) 1-23
11. Hylan T.R., Sundell K., and Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. Journal of Womens Health and Gender-Based Medicine 8 (1999) 1043-1052
12. Johnson S.R., McChesney C., and Bean J.A. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. Journal of Reproductive Medicine 33 (1988) 340-346
13. Mishell Jr. D.R. Premenstrual disorders: epidemiology and disease burden. American Journal of Managed Care 11 16 Suppl (2005) S473-S479
14. Pearlstein T.B., Bachmann G.A., Zacur H.A., and Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
15. Reilly M.C., Zbrozek A.S., and Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4 (1993) 353-365
16. Sculpher M.J., Pang F.S., Manca A., Drummond M.L., Golder S., Urdahl H., et al. Generalizability in economic evaluation studies in healthcare: a review and case studies. Health Technology Assessment 8 (2004) 49
17. Steiner M., Macdougall M., and Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Archives of Women's Mental Health 6 (2003) 203-209
18. Sternfeld B., Swindle R., Chawla A., Long S., and Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstetrics and Gynecology 99 (2002) 1014-1024
19. Yang M., Wallenstein G., Hagan M., Guo A., Chang J., and Kornstein S. Burden of premenstrual dysphoric disorder on health-related quality of life. Journal of Womens Health (Larchmont) 17 (2008) 113-121
20. Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., and Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics and Gynecology 106 (2005) 492-501
21. Yonkers K.A., Halbreich U., Freeman E., Brown C., Endicott J., Frank E., et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 278 (1997) 983-988